COVID-19 Vaccine Tested at Emory Spurs Immune Response in Older Adults
September 30, 2020
September 30, 2020
ATLANTA, Georgia, Sept. 30 (TNSJou) -- Emory University's Woodruff Health Sciences Center issued the following news release on Sept. 29:
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well tolerated and generates a strong immune response in older adults. A report published today in The New England Journal of Medicine (NEJM) describes the findings from the study, which was supported by the National Institute of Al . . .
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well tolerated and generates a strong immune response in older adults. A report published today in The New England Journal of Medicine (NEJM) describes the findings from the study, which was supported by the National Institute of Al . . .